Abstract B009: The Dutch childhood cancer genome project: Data-driven precision medicine and research

Abstract Despite improvements in cure rates, cancer is still the leading cause of disease-related deaths among children in high-income countries. As childhood cancers are rare in comparison to adult cancers, concerted efforts are needed to advance research and improve patient care. In The Netherlands, all childhood cancer care and most research has been concentrated in a single national center, the Princess Máxima Center for Pediatric Oncology. The institute’s centralized position enables uniform generation of data from patients across the country, that through federation with other initiatives can provide a unique contribution to tackle childhood cancer world-wide. Whole-exome sequencing, whole-genome sequencing and RNA-sequencing are routinely performed for diagnostic and research purposes, leading to a representative national dataset with little batch effects. Currently this data collection consists of ∼1000 patient samples with rich and uniform clinical data. This collection is expected to grow to ∼4,000 patient samples by 2028. Here, I will show how we use this rich, harmonized data resource to improve patient care and aid data-driven research into understanding the role of different types of somatic variation in tumor initiation and progression. First, by performing whole-exome sequencing and RNA-sequencing as standard-of-care we provide individualized diagnosis and treatment plans for precision medicine purposes. Second, by investigating complex genomic rearrangements in pediatric solid tumors we show that these occur in approximately half of the tumor samples and are likely highly pathogenic. Third, by performing integrative tumor driver identification, we identify events that are otherwise likely missed through more targeted approaches. Fourth, through the development of M 2024 Sep 5-8; Toronto, Ontario, Canada. Philadelphia (PA): AACR; Cancer Res 2024;84(17 Suppl):Abstract nr B009.